INM vs PRFX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The company exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe weakness across nearly all fundamental health dimensions. While the current ratio is high (5.94), this is offset by a catastrophic profit margin of -170.07% and declining year-over-year revenue growth of -26.20%. The stock is in a clear long-term death spiral, with a 5-year price change of -100% and a technical trend score of 0/100. Without a pivot to profitability or a significant capital infusion, the business model appears unsustainable.
PRFX exhibits severe financial distress, characterized by a Piotroski F-Score of 4/9, which barely places it in the 'stable' category despite catastrophic operating margins of -16,200%. The absence of an Altman Z-Score and Graham Number reflects a lack of positive earnings and stable valuation foundations. With a Price-to-Sales ratio of 135.62 and a 5-year price collapse of 99.7%, the company appears to be a speculative shell with virtually no meaningful revenue generation. While the current ratio of 1.78 provides a temporary liquidity cushion, the fundamental business model is currently non-viable.
Compare Another Pair
Related Comparisons
INM vs PRFX: Head-to-Head Comparison
This page compares InMed Pharmaceuticals Inc. (INM) and PRF Technologies Ltd. (PRFX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.